Carlsmed (CARL) Cost of Revenue (2024 - 2026)

Carlsmed (CARL) has reported Cost of Revenue for 3 consecutive years, with $9.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 51.91% year-over-year to $9.2 million; the trailing twelve-month figure through Jun 2026 stood at $37.7 million (up 58.35% YoY), and the FY2025 full-year result was $26.4 million, up 69.94% from the prior year.
• Cost of Revenue improved to $9.2 million in Q2 2026 per CARL's latest filing, from $7.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $17.5 million in Q4 2025 and bottomed at $1.5 million in Q2 2024.
• Historically, Cost of Revenue has averaged $7.0 million across 3 years, with a median of $6.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue jumped 296.84% in 2025, then surged 51.91% in 2026.
• Over 3 years, Cost of Revenue stood at $10.8 million in 2024, then surged by 61.89% to $17.5 million in 2025, then plunged by 47.71% to $9.2 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $9.2 million, $7.9 million, and $17.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.